CAR- PRISM (PRecision Intervention Smoldering Myeloma)
Active, not recruiting · Phase 2 · NCT05767359
Conditions: Multiple Myeloma, Smoldering Multiple Myeloma
At a glance
- Research payments reported, 2025
- $77,841
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 20
About the trial
- Sponsor
- Dana-Farber Cancer Institute (with Janssen Research & Development, LLC)
- Tested
- Ciltacabtagene Autoleucel (drug), Cyclophosphamide (drug), Fludarabine Phosphate (drug)
- Dates
- Started 2023-04-19; completion 2040-01-15
- Results posted
- Not yet
The goal of this research study is to test if ciltacabtagene autoleucel (cilta-cel) is safe and effective in treating participants with high-risk, smoldering myeloma. The names of the treatment interventions used in this study are: * Cilta-cel (or chimeric antigen receptor T cells) * Cyclophosphamide (a lymphodepleting chemotherapy) * Fludarabine (a lymphodepleting chemotherapy)
From ClinicalTrials.gov, last updated 2026-03-12. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Menarini Silicon Biosystems, Inc. reported $77,841 in research payments for this study in 2025 (23 payments).
Products named: Cellsearch
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Dana-Farber Cancer Institute $77,841
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.